[시장보고서]스마트 나노입자 암 치료 시장 분석 및 예측(-2035년) : 유형별, 제품별, 서비스별, 기술별, 용도별, 재료 유형별, 최종 사용자별, 기능성별, 단계별

스마트 나노입자 암 치료 시장 분석 및 예측(-2035년) : 유형별, 제품별, 서비스별, 기술별, 용도별, 재료 유형별, 최종 사용자별, 기능성별, 단계별

Smart Nanoparticle Cancer Treatments Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, Material Type, End User, Functionality, Stage

상품코드 : 1951809

리서치사 : Global Insight Services

발행일 : 2026년 02월

페이지 정보 : 영문 301 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,750

￦ 7,150,000

PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF, Excel 이용 범위와 동일합니다.

US $ 5,750

￦ 8,656,000

PDF & Excel (Site License)

PDF, Excel 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다.

US $ 6,750

￦ 10,161,000

PDF & Excel (Enterprise License)

PDF, Excel 보고서를 동일 기업의 전 세계 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF, Excel 이용 범위와 동일합니다.

한글목차

샘플 요청 목록에 추가

세계의 스마트 나노입자 암 치료 시장은 2024년 110억 달러에서 2034년까지 300억 달러로 확대되어 CAGR 약 12.2%를 나타낼 것으로 예측됩니다. 스마트 나노입자 암 치료 시장은 암세포를 정밀하게 표적으로 하도록 설계된 나노입자를 활용한 첨단 치료 솔루션을 포함하고 있습니다. 이러한 치료법은 제어된 방출과 생체이용률을 향상시키는 나노기술을 활용하여 부작용을 최소화하면서 약물 전달의 효율성을 높입니다. 본 시장은 암 이환율의 상승, 나노의료 기술의 발전, 맞춤형 의료에 대한 투자 증가에 의해 견인되고 있습니다. 스마트 나노입자에 있어서의 혁신은 보다 효과적이고 표적을 좁힌 암 치료에 대한 유망한 경로를 제공하여 종양학에 혁명을 가져올 가능성을 갖고 있습니다.

스마트 나노입자 암 치료 시장은 표적 약물 전달과 맞춤형 의료의 진보에 견인되어 견조한 성장이 예상됩니다. 약물 전달 시스템 분야가 가장 높은 성장률을 나타내고 있으며, 생체적합성과 다양한 치료제의 캡슐화 능력으로부터 지질계 나노입자가 주도적인 역할을 담당하고 있습니다. 폴리머계 나노입자는 이에 이어 약물의 제조 및 방출 프로파일에 범용성을 제공합니다. 영상 및 진단 부문은 2위 성장률을 나타내고, 양자점은 뛰어난 광학 특성에 의해 조기 암 검출을 강화하는 점에서 주목받고 있습니다. 자성 나노입자는 또한 치료 중 실시간 모니터링 기능을 제공할 가능성을 보여줍니다. 나노입자 설계에 대한 AI와 머신러닝의 통합이 진행되고 있으며, 치료 효과와 환자 결과의 최적화를 도모하고 있습니다. 제약기업과 연구기관의 제휴가 혁신을 가속화하여 수익성이 높은 기회를 창출하고 있습니다. 전신 독성의 감소와 표적 요법의 효과 향상에 대한 관심 증가가 시장의 추가 확대를 뒷받침하고 있습니다. 규제 측면의 지원과 R&D 투자 증가는 이 역동적인 시장 상황을 지원하는 중요한 요소입니다.

시장 세분화
유형	리포좀, 고분자 나노입자, 금속 나노입자, 덴드리머, 탄소나노튜브, 양자점, 나노캡슐
제품	치료용 나노입자, 진단용 나노입자, 다기능 나노입자
서비스	연구 개발, 임상시험, 규제 컨설팅, 제조 서비스
기술	표적 전달, 방출 조절, 나노캐리어, 표면 개질
적용	유방암, 폐암, 전립선암, 대장암, 뇌종양, 췌장암, 피부암
재료 유형	유기 재료, 무기 재료, 하이브리드 재료
최종 사용자	병원, 암 연구소, 제약 회사, 생명 공학 회사, 학술 기관
기능성	치료 진단, 바이오 이미징, 약물 전달, 유전자 전달
개발 단계	전임상 단계, 임상 단계, 상품화

스마트 나노입자 암 치료는 의약품 업계에서 큰 주목을 받고 있습니다. 시장 점유율의 대부분은 혁신적인 제품을 투입하는 선구적인 기업에 의해 점유되고 있습니다. 가격 전략은 진화를 계속하고 있으며, 이러한 치료법이 가지는 첨단 기술과 높은 효능으로 프리미엄 가격 설정이 정당화되고 있습니다. 신제품이 자주 출시되고 표적 요법의 최첨단 진보가 나타납니다. 암 치료에서 정밀성 수요의 높아짐과 합치하는 맞춤형 의료에 대한 중점이 놓여져 있습니다. 지리적으로는 선진지역이 최전선에 있으며 신흥 시장이 급속히 따라잡고 있습니다. 스마트 나노입자 암 치료 시장에서의 경쟁은 치열하고, 주요 기업은 지속적으로 서로를 벤치마크하고 있습니다. 규제의 영향은 특히 북미와 유럽에서 중요하며, 엄격한 기준이 시장 진입과 제품 수명주기를 규정하고 있습니다. 경쟁 구도은 시장 범위와 기술 능력의 확대를 목표로 전략적 제휴와 합병을 특징으로 합니다. 시장 데이터는 증가하는 R&D 투자와 유리한 규제 프레임워크를 뒷받침하는 견조한 성장 궤도를 시사합니다. 시장 전망은 유망하며 혁신과 전략적 연계가 확대를 추진하고 있습니다.

주요 동향과 촉진요인:

나노기술과 맞춤형 의료의 진보로 스마트 나노입자 암 치료 시장은 견조한 성장을 이루고 있습니다. 주요 동향은 스마트 나노입자와 표적 약물 전달 시스템의 통합을 포함하여 치료 효과 향상과 부작용 감소를 실현하고 있습니다. 이 혁신은 암 환자 증가와 보다 효과적인 치료법 수요 증가에 의해 추진되고 있습니다. 게다가 연구개발 투자 증가가 신규 나노입자 제제의 발견을 가속화하고 있습니다. 이러한 노력은 제약기업과 학술기관의 연계에 의해 지원되고, 혁신을 촉진하고 시장 상황을 확대하고 있습니다. 또 다른 중요한 촉진요인은 의료 종사자와 환자에서 나노 입자 기반 치료에 대한 인지도와 수용성 증가입니다. 또한, 나노입자 치료의 규제 당국에 의한 승인이 증가하고 있으며, 시장 확대에 유리한 환경을 제공합니다. 신흥 시장에서는 의료 인프라의 개선과 고급 치료에 대한 접근성이 확대됨에 따라 수익성이 높은 기회가 탄생하고 있습니다. 이 지역에 투자하는 기업들은 경쟁 우위를 확보할 가능성이 높습니다. 이러한 동향과 촉진요인의 융합은 시장의 지속적인 성장과 혁신의 가능성을 뒷받침하고 있습니다.

시장 규모 및 예측 : 유형별
- 리포솜
- 고분자 나노입자
- 금속 나노입자
- 덴드리머
- 탄소나노튜브
- 양자점
- 나노캡슐
시장 규모 및 예측 : 제품별
- 치료용 나노입자
- 진단용 나노입자
- 다기능 나노입자
시장 규모 및 예측 : 서비스별
- 연구개발
- 임상시험
- 규제 컨설팅
- 제조 서비스
시장 규모 및 예측 : 기술별
- 표적화 전달
- 방출 조절
- 나노캐리어
- 표면 개질
시장 규모 및 예측 : 용도별
- 유방암
- 폐암
- 전립선암
- 대장암
- 뇌종양
- 췌장암
- 피부암
시장 규모 및 예측 : 소재 유형별
- 유기 재료
- 무기 재료
- 하이브리드 재료
시장 규모 및 예측 : 최종 사용자별
- 병원
- 암 연구 기관
- 제약기업
- 바이오테크놀러지 기업
- 학술기관
시장 규모 및 예측 : 기능별
- 테라노스틱스
- 바이오 이미징
- 약물 전달
- 유전자 전달
시장 규모 및 예측 : 단계별
- 전임상 단계
- 임상
- 상품화

제5장 지역별 분석

북미
- 미국
- 캐나다
- 멕시코
라틴아메리카
- 브라질
- 아르헨티나
- 기타 라틴아메리카
아시아태평양
- 중국
- 인도
- 한국
- 일본
- 호주
- 대만
- 기타 아시아태평양
유럽
- 독일
- 프랑스
- 영국
- 스페인
- 이탈리아
- 기타 유럽
중동 및 아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 남아프리카
- 사하라 이남 아프리카
- 기타 중동 및 아프리카

제6장 시장 전략

수요 및 공급의 갭 분석
무역 및 물류상의 제약
가격, 비용, 마진의 동향
시장 침투
소비자 분석
규제 개요

제7장 경쟁 정보

시장 포지셔닝
시장 점유율
경쟁 벤치마킹
주요 기업의 전략

제8장 기업 프로파일

Cytimmune Sciences
Nanospectra Biosciences
Selecta Biosciences
Starpharma Holdings
Liquidia Technologies
Nanobiotix
BIND Therapeutics
Midatech Pharma
Nanocarrier Co
Celgene Corporation
Tarveda Therapeutics
Nanoprobes
Nano Valent Pharmaceuticals
Mag Force AG
Bio-Gate AG
Nanophase Technologies
Nanotherapeutics
Arrowhead Pharmaceuticals
Celsion Corporation
p Sivida Corp

제9장 당사에 대해서

JHS

영문 목차

영문목차

Smart Nanoparticle Cancer Treatments Market is anticipated to expand from $11 billion in 2024 to $30 billion by 2034, growing at a CAGR of approximately 12.2%. The Smart Nanoparticle Cancer Treatments Market encompasses advanced therapeutic solutions utilizing nanoparticles engineered to target cancer cells with precision. These treatments enhance drug delivery efficacy while minimizing side effects, leveraging nanotechnology for controlled release and improved bioavailability. The market is driven by rising cancer prevalence, technological advancements in nanomedicine, and increasing investments in personalized medicine. Innovations in smart nanoparticles are poised to revolutionize oncology, offering promising avenues for more effective and targeted cancer therapies.

The Smart Nanoparticle Cancer Treatments Market is poised for robust growth, driven by advancements in targeted drug delivery and personalized medicine. The drug delivery systems segment is the top-performing sub-segment, with lipid-based nanoparticles leading due to their biocompatibility and ability to encapsulate diverse therapeutic agents. Polymer-based nanoparticles follow closely, offering versatility in drug formulation and release profiles. The imaging and diagnostics segment is the second highest performing, with quantum dots gaining prominence for their superior optical properties, enhancing early cancer detection. Magnetic nanoparticles also show potential, providing real-time monitoring capabilities during treatment. The integration of AI and machine learning in nanoparticle design is emerging, optimizing treatment efficacy and patient outcomes. Collaborations between pharmaceutical companies and research institutions are accelerating innovation, creating lucrative opportunities. The growing emphasis on reducing systemic toxicity and enhancing targeted therapy effectiveness further propels market expansion. Regulatory support and increasing investment in R&D are key enablers of this dynamic market landscape.

Market Segmentation
Type	Liposomes, Polymeric Nanoparticles, Metallic Nanoparticles, Dendrimers, Carbon Nanotubes, Quantum Dots, Nanocapsules
Product	Therapeutic Nanoparticles, Diagnostic Nanoparticles, Multifunctional Nanoparticles
Services	Research and Development, Clinical Trials, Regulatory Consulting, Manufacturing Services
Technology	Targeted Delivery, Controlled Release, Nanocarriers, Surface Modification
Application	Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Cancer, Pancreatic Cancer, Skin Cancer
Material Type	Organic Materials, Inorganic Materials, Hybrid Materials
End User	Hospitals, Cancer Research Institutes, Pharmaceutical Companies, Biotechnology Companies, Academic Institutes
Functionality	Theranostics, Bioimaging, Drug Delivery, Gene Delivery
Stage	Preclinical, Clinical, Commercialized

Smart Nanoparticle Cancer Treatments are gaining significant traction in the pharmaceutical landscape. The market share is predominantly held by pioneering companies launching innovative products. Pricing strategies are evolving, with premium pricing being justified by the advanced technology and enhanced efficacy of these treatments. New product launches are frequent, showcasing cutting-edge advancements in targeted therapies. The emphasis is on personalized medicine, which aligns with the growing demand for precision in cancer treatment. Geographically, developed regions are at the forefront, with emerging markets catching up rapidly. Competition in the Smart Nanoparticle Cancer Treatments Market is intense, with key players continuously benchmarking against each other. Regulatory influences play a crucial role, particularly in North America and Europe, where stringent standards dictate market entry and product lifecycle. The competitive landscape is characterized by strategic partnerships and mergers, aiming to expand market reach and technological capabilities. Market data suggests a robust growth trajectory, propelled by increasing R&D investments and favorable regulatory frameworks. The market's future is promising, with innovation and strategic collaborations driving expansion.

Geographical Overview:

The Smart Nanoparticle Cancer Treatments Market is witnessing substantial growth, with dynamic developments across various regions. North America is at the forefront, propelled by advanced healthcare infrastructure and extensive research initiatives. The region's commitment to innovation and early adoption of cutting-edge technologies bolsters its market leadership. Europe follows, driven by robust government support and increasing investments in biotechnology research. The region's focus on precision medicine and personalized treatment enhances its market potential. In Asia Pacific, the market is expanding rapidly, spurred by rising healthcare expenditure and significant advancements in nanotechnology. Countries such as China and India are emerging as lucrative markets due to their large patient populations and increasing demand for effective cancer treatments. Latin America and the Middle East & Africa are also showing promising growth. In Latin America, improving healthcare infrastructure and growing awareness of advanced treatments are key drivers. Meanwhile, the Middle East & Africa region is recognizing the potential of smart nanoparticle technology to revolutionize cancer care.

Global tariffs and geopolitical tensions are significantly influencing the Smart Nanoparticle Cancer Treatments Market. Japan and South Korea are enhancing domestic R&D and production capabilities to mitigate tariff impacts and reduce reliance on foreign suppliers. China's strategic focus on self-reliance is accelerating its advancements in nanotechnology, while Taiwan, despite its semiconductor prowess, remains vulnerable to geopolitical tensions. The global market for smart nanoparticle cancer treatments is expanding, driven by technological advancements and increasing cancer prevalence. By 2035, the market is expected to witness robust growth, fueled by innovation and strategic alliances. Middle East conflicts are exerting pressure on energy prices, which in turn affects global supply chains, potentially leading to increased production costs and logistical challenges for this burgeoning market.

Key Trends and Drivers:

The Smart Nanoparticle Cancer Treatments Market is experiencing robust growth due to advancements in nanotechnology and personalized medicine. A key trend is the integration of smart nanoparticles with targeted drug delivery systems, enhancing treatment efficacy and reducing side effects. This innovation is driven by the increasing prevalence of cancer and the demand for more effective therapeutic options. Moreover, the rise in research and development investments is accelerating the discovery of novel nanoparticle formulations. These efforts are supported by collaborations between pharmaceutical companies and academic institutions, fostering innovation and expanding the market landscape. Another significant driver is the growing awareness and acceptance of nanoparticle-based therapies among healthcare professionals and patients. Additionally, regulatory approvals for nanoparticle treatments are increasing, providing a conducive environment for market expansion. Emerging markets are presenting lucrative opportunities as healthcare infrastructure improves and access to advanced treatments becomes more widespread. Companies investing in these regions are likely to gain a competitive advantage. The convergence of these trends and drivers underscores the market's potential for sustained growth and innovation.

Research Scope:

Estimates and forecasts the overall market size across type, application, and region.
Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

1 Executive Summary

1.1 Market Size and Forecast
1.2 Market Overview
1.3 Market Snapshot
1.4 Regional Snapshot
1.5 Strategic Recommendations
1.6 Analyst Notes

2 Market Highlights

2.1 Key Market Highlights by Type
2.2 Key Market Highlights by Product
2.3 Key Market Highlights by Services
2.4 Key Market Highlights by Technology
2.5 Key Market Highlights by Application
2.6 Key Market Highlights by Material Type
2.7 Key Market Highlights by End User
2.8 Key Market Highlights by Functionality
2.9 Key Market Highlights by Stage

3 Market Dynamics

3.1 Macroeconomic Analysis
3.2 Market Trends
3.3 Market Drivers
3.4 Market Opportunities
3.5 Market Restraints
3.6 CAGR Growth Analysis
3.7 Impact Analysis
3.8 Emerging Markets
3.9 Technology Roadmap
3.10 Strategic Frameworks
- 3.10.1 PORTER's 5 Forces Model
- 3.10.2 ANSOFF Matrix
- 3.10.3 4P's Model
- 3.10.4 PESTEL Analysis

4 Segment Analysis

4.1 Market Size & Forecast by Type (2020-2035)
- 4.1.1 Liposomes
- 4.1.2 Polymeric Nanoparticles
- 4.1.3 Metallic Nanoparticles
- 4.1.4 Dendrimers
- 4.1.5 Carbon Nanotubes
- 4.1.6 Quantum Dots
- 4.1.7 Nanocapsules
4.2 Market Size & Forecast by Product (2020-2035)
- 4.2.1 Therapeutic Nanoparticles
- 4.2.2 Diagnostic Nanoparticles
- 4.2.3 Multifunctional Nanoparticles
4.3 Market Size & Forecast by Services (2020-2035)
- 4.3.1 Research and Development
- 4.3.2 Clinical Trials
- 4.3.3 Regulatory Consulting
- 4.3.4 Manufacturing Services
4.4 Market Size & Forecast by Technology (2020-2035)
- 4.4.1 Targeted Delivery
- 4.4.2 Controlled Release
- 4.4.3 Nanocarriers
- 4.4.4 Surface Modification
4.5 Market Size & Forecast by Application (2020-2035)
- 4.5.1 Breast Cancer
- 4.5.2 Lung Cancer
- 4.5.3 Prostate Cancer
- 4.5.4 Colorectal Cancer
- 4.5.5 Brain Cancer
- 4.5.6 Pancreatic Cancer
- 4.5.7 Skin Cancer
4.6 Market Size & Forecast by Material Type (2020-2035)
- 4.6.1 Organic Materials
- 4.6.2 Inorganic Materials
- 4.6.3 Hybrid Materials
4.7 Market Size & Forecast by End User (2020-2035)
- 4.7.1 Hospitals
- 4.7.2 Cancer Research Institutes
- 4.7.3 Pharmaceutical Companies
- 4.7.4 Biotechnology Companies
- 4.7.5 Academic Institutes
4.8 Market Size & Forecast by Functionality (2020-2035)
- 4.8.1 Theranostics
- 4.8.2 Bioimaging
- 4.8.3 Drug Delivery
- 4.8.4 Gene Delivery
4.9 Market Size & Forecast by Stage (2020-2035)
- 4.9.1 Preclinical
- 4.9.2 Clinical
- 4.9.3 Commercialized

5 Regional Analysis

5.1 Global Market Overview
5.2 North America Market Size (2020-2035)
- 5.2.1 United States
  - 5.2.1.1 Type
  - 5.2.1.2 Product
  - 5.2.1.3 Services
  - 5.2.1.4 Technology
  - 5.2.1.5 Application
  - 5.2.1.6 Material Type
  - 5.2.1.7 End User
  - 5.2.1.8 Functionality
  - 5.2.1.9 Stage
- 5.2.2 Canada
  - 5.2.2.1 Type
  - 5.2.2.2 Product
  - 5.2.2.3 Services
  - 5.2.2.4 Technology
  - 5.2.2.5 Application
  - 5.2.2.6 Material Type
  - 5.2.2.7 End User
  - 5.2.2.8 Functionality
  - 5.2.2.9 Stage
- 5.2.3 Mexico
  - 5.2.3.1 Type
  - 5.2.3.2 Product
  - 5.2.3.3 Services
  - 5.2.3.4 Technology
  - 5.2.3.5 Application
  - 5.2.3.6 Material Type
  - 5.2.3.7 End User
  - 5.2.3.8 Functionality
  - 5.2.3.9 Stage
5.3 Latin America Market Size (2020-2035)
- 5.3.1 Brazil
  - 5.3.1.1 Type
  - 5.3.1.2 Product
  - 5.3.1.3 Services
  - 5.3.1.4 Technology
  - 5.3.1.5 Application
  - 5.3.1.6 Material Type
  - 5.3.1.7 End User
  - 5.3.1.8 Functionality
  - 5.3.1.9 Stage
- 5.3.2 Argentina
  - 5.3.2.1 Type
  - 5.3.2.2 Product
  - 5.3.2.3 Services
  - 5.3.2.4 Technology
  - 5.3.2.5 Application
  - 5.3.2.6 Material Type
  - 5.3.2.7 End User
  - 5.3.2.8 Functionality
  - 5.3.2.9 Stage
- 5.3.3 Rest of Latin America
  - 5.3.3.1 Type
  - 5.3.3.2 Product
  - 5.3.3.3 Services
  - 5.3.3.4 Technology
  - 5.3.3.5 Application
  - 5.3.3.6 Material Type
  - 5.3.3.7 End User
  - 5.3.3.8 Functionality
  - 5.3.3.9 Stage
5.4 Asia-Pacific Market Size (2020-2035)
- 5.4.1 China
  - 5.4.1.1 Type
  - 5.4.1.2 Product
  - 5.4.1.3 Services
  - 5.4.1.4 Technology
  - 5.4.1.5 Application
  - 5.4.1.6 Material Type
  - 5.4.1.7 End User
  - 5.4.1.8 Functionality
  - 5.4.1.9 Stage
- 5.4.2 India
  - 5.4.2.1 Type
  - 5.4.2.2 Product
  - 5.4.2.3 Services
  - 5.4.2.4 Technology
  - 5.4.2.5 Application
  - 5.4.2.6 Material Type
  - 5.4.2.7 End User
  - 5.4.2.8 Functionality
  - 5.4.2.9 Stage
- 5.4.3 South Korea
  - 5.4.3.1 Type
  - 5.4.3.2 Product
  - 5.4.3.3 Services
  - 5.4.3.4 Technology
  - 5.4.3.5 Application
  - 5.4.3.6 Material Type
  - 5.4.3.7 End User
  - 5.4.3.8 Functionality
  - 5.4.3.9 Stage
- 5.4.4 Japan
  - 5.4.4.1 Type
  - 5.4.4.2 Product
  - 5.4.4.3 Services
  - 5.4.4.4 Technology
  - 5.4.4.5 Application
  - 5.4.4.6 Material Type
  - 5.4.4.7 End User
  - 5.4.4.8 Functionality
  - 5.4.4.9 Stage
- 5.4.5 Australia
  - 5.4.5.1 Type
  - 5.4.5.2 Product
  - 5.4.5.3 Services
  - 5.4.5.4 Technology
  - 5.4.5.5 Application
  - 5.4.5.6 Material Type
  - 5.4.5.7 End User
  - 5.4.5.8 Functionality
  - 5.4.5.9 Stage
- 5.4.6 Taiwan
  - 5.4.6.1 Type
  - 5.4.6.2 Product
  - 5.4.6.3 Services
  - 5.4.6.4 Technology
  - 5.4.6.5 Application
  - 5.4.6.6 Material Type
  - 5.4.6.7 End User
  - 5.4.6.8 Functionality
  - 5.4.6.9 Stage
- 5.4.7 Rest of APAC
  - 5.4.7.1 Type
  - 5.4.7.2 Product
  - 5.4.7.3 Services
  - 5.4.7.4 Technology
  - 5.4.7.5 Application
  - 5.4.7.6 Material Type
  - 5.4.7.7 End User
  - 5.4.7.8 Functionality
  - 5.4.7.9 Stage
5.5 Europe Market Size (2020-2035)
- 5.5.1 Germany
  - 5.5.1.1 Type
  - 5.5.1.2 Product
  - 5.5.1.3 Services
  - 5.5.1.4 Technology
  - 5.5.1.5 Application
  - 5.5.1.6 Material Type
  - 5.5.1.7 End User
  - 5.5.1.8 Functionality
  - 5.5.1.9 Stage
- 5.5.2 France
  - 5.5.2.1 Type
  - 5.5.2.2 Product
  - 5.5.2.3 Services
  - 5.5.2.4 Technology
  - 5.5.2.5 Application
  - 5.5.2.6 Material Type
  - 5.5.2.7 End User
  - 5.5.2.8 Functionality
  - 5.5.2.9 Stage
- 5.5.3 United Kingdom
  - 5.5.3.1 Type
  - 5.5.3.2 Product
  - 5.5.3.3 Services
  - 5.5.3.4 Technology
  - 5.5.3.5 Application
  - 5.5.3.6 Material Type
  - 5.5.3.7 End User
  - 5.5.3.8 Functionality
  - 5.5.3.9 Stage
- 5.5.4 Spain
  - 5.5.4.1 Type
  - 5.5.4.2 Product
  - 5.5.4.3 Services
  - 5.5.4.4 Technology
  - 5.5.4.5 Application
  - 5.5.4.6 Material Type
  - 5.5.4.7 End User
  - 5.5.4.8 Functionality
  - 5.5.4.9 Stage
- 5.5.5 Italy
  - 5.5.5.1 Type
  - 5.5.5.2 Product
  - 5.5.5.3 Services
  - 5.5.5.4 Technology
  - 5.5.5.5 Application
  - 5.5.5.6 Material Type
  - 5.5.5.7 End User
  - 5.5.5.8 Functionality
  - 5.5.5.9 Stage
- 5.5.6 Rest of Europe
  - 5.5.6.1 Type
  - 5.5.6.2 Product
  - 5.5.6.3 Services
  - 5.5.6.4 Technology
  - 5.5.6.5 Application
  - 5.5.6.6 Material Type
  - 5.5.6.7 End User
  - 5.5.6.8 Functionality
  - 5.5.6.9 Stage
5.6 Middle East & Africa Market Size (2020-2035)
- 5.6.1 Saudi Arabia
  - 5.6.1.1 Type
  - 5.6.1.2 Product
  - 5.6.1.3 Services
  - 5.6.1.4 Technology
  - 5.6.1.5 Application
  - 5.6.1.6 Material Type
  - 5.6.1.7 End User
  - 5.6.1.8 Functionality
  - 5.6.1.9 Stage
- 5.6.2 United Arab Emirates
  - 5.6.2.1 Type
  - 5.6.2.2 Product
  - 5.6.2.3 Services
  - 5.6.2.4 Technology
  - 5.6.2.5 Application
  - 5.6.2.6 Material Type
  - 5.6.2.7 End User
  - 5.6.2.8 Functionality
  - 5.6.2.9 Stage
- 5.6.3 South Africa
  - 5.6.3.1 Type
  - 5.6.3.2 Product
  - 5.6.3.3 Services
  - 5.6.3.4 Technology
  - 5.6.3.5 Application
  - 5.6.3.6 Material Type
  - 5.6.3.7 End User
  - 5.6.3.8 Functionality
  - 5.6.3.9 Stage
- 5.6.4 Sub-Saharan Africa
  - 5.6.4.1 Type
  - 5.6.4.2 Product
  - 5.6.4.3 Services
  - 5.6.4.4 Technology
  - 5.6.4.5 Application
  - 5.6.4.6 Material Type
  - 5.6.4.7 End User
  - 5.6.4.8 Functionality
  - 5.6.4.9 Stage
- 5.6.5 Rest of MEA
  - 5.6.5.1 Type
  - 5.6.5.2 Product
  - 5.6.5.3 Services
  - 5.6.5.4 Technology
  - 5.6.5.5 Application
  - 5.6.5.6 Material Type
  - 5.6.5.7 End User
  - 5.6.5.8 Functionality
  - 5.6.5.9 Stage

6 Market Strategy

6.1 Demand-Supply Gap Analysis
6.2 Trade & Logistics Constraints
6.3 Price-Cost-Margin Trends
6.4 Market Penetration
6.5 Consumer Analysis
6.6 Regulatory Snapshot

7 Competitive Intelligence

7.1 Market Positioning
7.2 Market Share
7.3 Competition Benchmarking
7.4 Top Company Strategies

8 Company Profiles

8.1 Cytimmune Sciences
- 8.1.1 Overview
- 8.1.2 Product Summary
- 8.1.3 Financial Performance
- 8.1.4 SWOT Analysis
8.2 Nanospectra Biosciences
- 8.2.1 Overview
- 8.2.2 Product Summary
- 8.2.3 Financial Performance
- 8.2.4 SWOT Analysis
8.3 Selecta Biosciences
- 8.3.1 Overview
- 8.3.2 Product Summary
- 8.3.3 Financial Performance
- 8.3.4 SWOT Analysis
8.4 Starpharma Holdings
- 8.4.1 Overview
- 8.4.2 Product Summary
- 8.4.3 Financial Performance
- 8.4.4 SWOT Analysis
8.5 Liquidia Technologies
- 8.5.1 Overview
- 8.5.2 Product Summary
- 8.5.3 Financial Performance
- 8.5.4 SWOT Analysis
8.6 Nanobiotix
- 8.6.1 Overview
- 8.6.2 Product Summary
- 8.6.3 Financial Performance
- 8.6.4 SWOT Analysis
8.7 BIND Therapeutics
- 8.7.1 Overview
- 8.7.2 Product Summary
- 8.7.3 Financial Performance
- 8.7.4 SWOT Analysis
8.8 Midatech Pharma
- 8.8.1 Overview
- 8.8.2 Product Summary
- 8.8.3 Financial Performance
- 8.8.4 SWOT Analysis
8.9 Nanocarrier Co
- 8.9.1 Overview
- 8.9.2 Product Summary
- 8.9.3 Financial Performance
- 8.9.4 SWOT Analysis
8.10 Celgene Corporation
- 8.10.1 Overview
- 8.10.2 Product Summary
- 8.10.3 Financial Performance
- 8.10.4 SWOT Analysis
8.11 Tarveda Therapeutics
- 8.11.1 Overview
- 8.11.2 Product Summary
- 8.11.3 Financial Performance
- 8.11.4 SWOT Analysis
8.12 Nanoprobes
- 8.12.1 Overview
- 8.12.2 Product Summary
- 8.12.3 Financial Performance
- 8.12.4 SWOT Analysis
8.13 Nano Valent Pharmaceuticals
- 8.13.1 Overview
- 8.13.2 Product Summary
- 8.13.3 Financial Performance
- 8.13.4 SWOT Analysis
8.14 Mag Force AG
- 8.14.1 Overview
- 8.14.2 Product Summary
- 8.14.3 Financial Performance
- 8.14.4 SWOT Analysis
8.15 Bio-Gate AG
- 8.15.1 Overview
- 8.15.2 Product Summary
- 8.15.3 Financial Performance
- 8.15.4 SWOT Analysis
8.16 Nanophase Technologies
- 8.16.1 Overview
- 8.16.2 Product Summary
- 8.16.3 Financial Performance
- 8.16.4 SWOT Analysis
8.17 Nanotherapeutics
- 8.17.1 Overview
- 8.17.2 Product Summary
- 8.17.3 Financial Performance
- 8.17.4 SWOT Analysis
8.18 Arrowhead Pharmaceuticals
- 8.18.1 Overview
- 8.18.2 Product Summary
- 8.18.3 Financial Performance
- 8.18.4 SWOT Analysis
8.19 Celsion Corporation
- 8.19.1 Overview
- 8.19.2 Product Summary
- 8.19.3 Financial Performance
- 8.19.4 SWOT Analysis
8.20 p Sivida Corp
- 8.20.1 Overview
- 8.20.2 Product Summary
- 8.20.3 Financial Performance
- 8.20.4 SWOT Analysis

9 About Us

9.1 About Us
9.2 Research Methodology
9.3 Research Workflow
9.4 Consulting Services
9.5 Our Clients
9.6 Client Testimonials
9.7 Contact Us